Last week was a big week for Wisconsin.
Though California recently made the extraordinary announcement to fund $3 billion in new stem-cell research in the wake of President Bushs policy (which severely limits and restricts federal government-associated research in this area), Wisconsin is the state where such research was pioneered.
<......Full article >>>
ommerce Cory Nettles). Also present was the State of Wisconsin Investment Board (SWIB), which manages $69 billion and is the ninth-largest institutional investor of public pension fund assets in the U.S. and the 18th largest in the world.
SWIB is a big investor in biotech and pharmaceuticals around the country. SWIB has put $150 million on the table to fund early and seed-stage life scien......Full article >>>
ovide that kind of funding as most of the VCs present on average put in perhaps $500,000 to $750,000 per deal.
The Wisconsin Technology Council shouldnt feel that bad. The recent iBIOMarketplace annual meeting in Illinois, which also had about 400 or so people, had a similar representation of VCs. By the way, there is a Midwest life science VC network called the Midwest Health Investors N......Full article >>>
toric development of technology in Wisconsin:
- From 1850 to 1900: Wisconsin focused on the development of the trees and forestry for the timber and lumber industries.
- 1900 to 1950: Development of ore for the steel industry was key in the state.
- 1950 to 2000: The development of crops and dairy industry for the agricultural industry.
- 2000 to 2050: The development of intellectual ......
Full article >>>
he Wisconsin Technology Council should be commended for a good show. Wake up on the east and west coasts as there are some very good things going on here in the Midwest. After all, Wisconsin and much of the Midwest is the third coast.
See you next week!
Michael S. Rosen is president and CEO of Barbeau Pharma and a founder and board member of the
Source:wistechnology.com By Michael Rosen 11/22/04Related biology technology :1
. Third Wave files countersuit vs. Digene in patent case2
. Third Wave reports net loss of $18.9M for 20063
. Stratagene to pay Third Wave $10.75M in patent case4
. Third Wave responds to Digene patent lawsuit5
. Third Wave seeks approval of Cystic Fibrosis test6
. Third Wave Technologies to raise $14.9M through private debt7
. Third Wave reports $5.2M third quarter loss8
. Third Wave reports another loss, stronger sales9
. Napier joins board of Third Wave Technologies10
. Third Waves revenues rebound11
. Third Wave reports clinical growth, continued loss